SCHEMBL505075

SCHEMBL505075

CC1(C)CN(C(=O)O)CCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23579282 0.81
SCHEMBL17438446 0.81
SCHEMBL30782515 0.81
SCHEMBL1292436 0.81
SCHEMBL6308517 0.77 GRM5 (0.48)
SCHEMBL6120473 0.76
SCHEMBL2159192 0.76 CRBN (0.33)
SCHEMBL517374 0.75 NR1H2 (0.46)
SCHEMBL20400106 0.75 SMN1; SMN2 (0.33)
SCHEMBL20600386 0.74 GRM5 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230405016-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS SAGIMET BIOSCIENCES INC. 2023-12-21 US disclosed
WO-2023064588-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY (US) 2023-04-20 WO disclosed
US-11622968-B2 Heterocyclic modulators of lipid synthesis SAGIMET BIOSCIENCES INC. (US) 2023-04-11 US disclosed
WO-2022199611-A1 HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF 上海海雁医药科技有限公司 2022-09-29 WO disclosed
US-20220296605-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS SAGIMET BIOSCIENCES INC. 2022-09-22 US disclosed
EP-3890829-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) Almac Discovery Limited (GB) 2021-10-13 EP disclosed
EP-3883928-A1 GLP-1R AGONISTS AND USES THEREOF Qilu Regor Therapeutics Inc. (CN) 2021-09-29 EP disclosed
US-11034690-B2 Heterocyclic modulators of lipid synthesis Saginiet Biosciences Inc. (US) 2021-06-15 US disclosed
EP-3728203-A1 DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS ChemoCentryx, Inc. (US) 2020-10-28 EP disclosed
WO-2020115501-A1 PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2020-06-11 WO disclosed
US-20090227601-A1 Bradykinin 1 Receptor Antagonists AMGEN INC. (US) 2009-09-10 US disclosed
WO-2009065919-A2 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-28 WO disclosed
EP-1963285-A1 BRADYKININ 1 RECEPTOR ANTAGONISTS Amgen Inc. (US) 2008-09-03 EP disclosed
CN-101218234-A Phenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMACEUTICALS SA (CH) 2008-07-09 CN disclosed
WO-2008060568-A2 AMIDE-SUBSTITUTED ARYL PIPERIDINES NEUROGEN CORPORATION (US) 2008-05-22 WO disclosed
CN-1997642-A 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones JANSSEN PHARMACEUTICA NV (BE) 2007-07-11 CN disclosed
WO-2007067629-A1 BRADYKININ 1 RECEPTOR ANTAGONISTS AMGEN INC. (US) 2007-06-14 WO disclosed
EP-1673341-A1 TETRAHYDROPYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2006-06-28 EP disclosed
CN-1671711-A Calcitonin gene related peptide receptor antagonists BRISTOL MYERS SQUIBB CO (US) 2005-09-21 CN disclosed
WO-2005040120-A1 TETRAHYDROPYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2005-05-06 WO disclosed